Abstract：
Despite being the focal point of decades of research, female breast cancer (BC) continues to be one of the most lethal cancers in the world. Given that 80 % of all diagnosed BC cases are estrogen receptor-positive (ER+) with carcinogenesis driven by estrogen-ERα signalling, current standard of care (SOC) hormone therapies are geared towards modulating the function and expression levels of estrogen and its receptors, ERα and ERβ. Currently, aromatase inhibitors (AIs), selective ER modulators (SERMs) and selective ER degraders (SERDs) are clinically prescribed for the management and treatment of ER+ BC, with the anti-aromatase activity of AIs abrogating estrogen biosynthesis, while the anti-estrogenic SERMs and SERDs antagonise and degrade the ER, respectively. The use of SOC hormone therapies is, however, significantly hampered by the onset of severe side-effects and the development of resistance. Given that numerous studies have reported on the beneficial effects of plant compounds and/or extracts and the multiple pathways through which they target ER+ breast carcinogenesis, recent research has focused on the use of dietary chemopreventive agents for BC management. When combined with SOC treatments, several of these plant components and/or extracts have demonstrated improved efficacy and/or synergistic impact. Moreover, despite a lack of in vivo investigations, plant products are generally reported to have a lower side-effect profile than SOC therapies and are therefore thought to be a safer therapeutic choice. Thus, the current review summarizes the findings from the last five years regarding the anti-aromatase and anti-estrogenic activity of plant products, as well as their synergistic anti-ER+ BC effects in combination with SOC therapies.
摘要：
尽管是几十年研究的焦点，女性乳腺癌（BC）仍然是世界上最致命的癌症之一。鉴于所有确诊的BC病例中有80％是雌激素受体阳性（ER），其致癌作用由雌激素-ERα信号驱动，目前的标准护理（SOC）激素疗法旨在调节雌激素及其受体的功能和表达水平，ERα和ERβ。目前,芳香化酶抑制剂（AI），选择性ER调节剂（SERM）和选择性ER降解剂（SERD）在临床上被规定用于ER+BC的管理和治疗，随着AIs的抗芳香化酶活性消除雌激素的生物合成，而抗雌激素SERM和SERD拮抗和降解ER，分别。使用SOC激素疗法是，然而,严重副作用的发作和耐药性的发展显着阻碍。鉴于许多研究已经报道了植物化合物和/或提取物的有益作用以及它们靶向ER+乳腺癌发生的多种途径，最近的研究集中在使用饮食化学预防剂进行BC管理。当与SOC治疗相结合时，这些植物组分和/或提取物中的几种已经显示出改善的功效和/或协同影响。此外，尽管缺乏体内研究，据报道,植物产品的副作用通常低于SOC疗法,因此被认为是更安全的治疗选择.因此，本综述总结了过去五年关于植物产品抗芳香化酶和抗雌激素活性的发现，以及它们与SOC疗法组合的协同抗ER+BC效应。
